TLX

1.54%

$20.44 telix pharmaceuticals limited

If Telix get to be the first movers with a PSMA-labelled...

First 4 Last

Share
Profile

Follow
eieio

3,780 Posts.

63

04/08/19

09:00

Post #: 39848302
Share

Originally posted by ajostu ↑

So two interesting anns today.

The Merck ann is interesting if vague. I couldn't help but feel (maybe a bit cynically) that the line about reporting obligations was put in to (a) cover for the lack of detail and (b) play peek-a-boo a bit.

Why is the Merck ann interesting? Because every bio loves to go on about how interested Big Pharma are in them. I've learned to switch off whenever a company says that unless they can provide some definite piece of evidence that it's true. So count this as evidence.

This Lancet article is interesting for several reasons. First of all it indirectly links back to the question of reimbursement rates: the article compares illumet with Axumin, which gets US$3000 reimbursement and is clearly in Telix's sights. It also supports the hypothesis that the FDA might look positively on the NDA application

Secondly, and I didn't notice until I reread it, it mentions that the pre-NDA FDA meeting has happened (27th Jul). This is a bit late (it was promised for Q2) but that may well be a matter of fitting in with the FDA. Getting FDA bookings seems to be a slow process. However based on the last FDA Phase III ann (Jun 17th meeting, Jul 15th ann) we can anticipate the ann for this coming out in about a month

Thirdly, it's an article in Lancet Oncology. Now I don't want to sound like a journal snob, but this is a big deal. This journal has a very high impact factor and as their own webpage puts it is in the top three of 200 odd oncology journals. Again this compares with a lot of other bios who will breathlessly tell you about the poster they've presented at some conference or the journal article that comes out three years after the ASX ann in the Journal Of We Promise You This Has High Impact Even Though You've Never Heard Of It. So again this lends weight that there's a good chance the FDA will approve it because It's Much Better Than What's Out There is a damn good reason.

I can't remember if it was Telix or Chris B, but one of the two has a snapshot of the key pieces of info from the Lancet paper on their twitter feed (enough to be informatice but not enough to get them into copyright trouble.) It's worth keeping an eye on these two twitter feeds. While they don't (of course) tell you anything the market doesn't already know, they're still useful for "the vibe".

Summary version: while FDA approval is never a fait accomplit, this looks about as close as it gets. While reimbursement rates are never guaranteed, this looks about as close as it gets. While a Big Pharma takeover is never guaranteed, there's now evidence that shows the possibility isn't a fantasy.

Expand

If Telix get to be the first movers with a PSMA-labelled radio-isotope suitable for PET scanning then they might well be on to a winner. Question remains: will they be the first?

Last edited by eieio: 04/08/19

TLX Price at posting: $1.54 Sentiment: Hold Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

The winners & losers on market if negative gearing were gone

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

The market's shrugged at China's stimulus measures all year. Why is this one different?

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

First 4 Last

Add TLX (ASX) to my watchlist

(20min delay)
Last $20.44		Change -0.320(1.54%)		Mkt cap ! $6.840B

Open	High	Low	Value	Volume
$20.79	$21.00	$20.22	$19.41M	945.3K

Buyers (Bids)

No.	Vol.	Price($)
1	500	$20.42

Sellers (Offers)

Price($)	Vol.	No.
$20.46	45	1

View Market Depth

No.	Vol.	Price($)
1	500	20.420
1	2000	20.330
1	250	20.250
1	495	20.230
1	1000	20.200

Price($)	Vol.	No.
20.630	3000	1
20.750	2000	1
20.970	143	1
20.990	1550	2
21.000	9256	3

Last trade - 16.10pm 27/09/2024 (20 minute delay)

TLX (ASX) Chart

If Telix get to be the first movers with a PSMA-labelled...

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

The winners & losers on market if negative gearing were gone

ACCC seeks Olam divestments before it can buy Namoi Cotton

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

KalGold rolls out detailed aeromagnetic survey across Pinjin project

The market's shrugged at China's stimulus measures all year. Why is this one different?

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

If Telix get to be the first movers with a PSMA-labelled...

Top Stories

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

The winners & losers on market if negative gearing were gone

ACCC seeks Olam divestments before it can buy Namoi Cotton

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

KalGold rolls out detailed aeromagnetic survey across Pinjin project

The market's shrugged at China's stimulus measures all year. Why is this one different?

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News